Stocks and Investing Stocks and Investing
Mon, October 31, 2022
Sun, October 30, 2022

Paul Matteis Maintained (VRTX) at Hold and Held Target at $289 on, Oct 30th, 2022


Published on 2024-10-27 23:45:54 - WOPRAI, Paul Matteis
  Print publication without navigation


Paul Matteis of Stifel, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold and Held Target at $289 on, Oct 30th, 2022.

Paul has made no other calls on VRTX in the last 4 months.



There are 12 other peers that have a rating on VRTX. Out of the 12 peers that are also analyzing VRTX, 4 agree with Paul's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold with Increased Target to $288 on, Friday, October 28th, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $285 on, Friday, October 28th, 2022
  • Do Kim of "Piper Sandler" Maintained at Hold with Increased Target to $288 on, Wednesday, August 17th, 2022
  • Brian Skorney of "Baird" Maintained at Hold and Held Target at $250 on, Friday, August 5th, 2022


These are the ratings of the 8 analyists that currently disagree with Paul


  • Michael Yee of "Jefferies" Maintained at Strong Buy and Held Target at $340 on, Friday, October 28th, 2022
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $335 on, Friday, October 28th, 2022
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $313 on, Friday, October 28th, 2022
  • Phil Nadeau of "TD Cowen" Maintained at Buy with Increased Target to $330 on, Friday, October 28th, 2022
  • Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $327 on, Monday, October 24th, 2022
  • Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $337 on, Friday, October 21st, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $300 on, Friday, August 5th, 2022
  • Olivia Brayer of "Cantor Fitzgerald" Initiated at Buy and Held Target at $365 on, Wednesday, July 13th, 2022
Contributing Sources